The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular degeneration drug development, and Ever Supreme Bio Technology’s cell therapy progress.
New Gongwin-KY lung cancer drug cleared for marketing in China (Healthcare+ B2B)
Gongwin-KY announced that its new drug, PTS302, for the treatment of lung cancer, has been approved by the China Drug Administration and is expected to be officially licensed soon.
PharmaEssentia named Therapeutics Solution of the Year at the second annual BioTech Breakthrough Awards (Healthcare+ B2B)
At the second annual BioTech Breakthrough Awards in the United States, Taiwan’s PharmaEssentia won the “Therapeutics Solution of the Year” award, becoming the only Taiwanese biotech to receive the award.
PharmaEngine’s first-line pancreatic cancer drug Onivyde shows clinical promise (CNyes, in Chinese)
Clinical data from a global pivotal trial for PharmaEngine’s combination therapy pancreatic cancer drug, Onivyde, for first-line pancreatic cancer has shown clinical significance, the company reported, along with its plans to further organize the data and submit it to the US FDA early next year.
Anxo Pharmaceutical alliance with Genovior Biotech (GBI Monthly, in Chinese)
Tainan-based drug delivery technology development company, Anxo Pharmaceutical, recently announced it has signed an alliance with Genovior Biotech to access its PIC/S GMP-certified sterile drug and preparation production lines and process experience. The companies plan to jointly build a nano-injection production line to produce the first new generation of long-acting injection-form drugs for psychiatric use in the China market.
ITRI and Metagone Biotech partner for glaucoma and macular degeneration drug development (Healthcare+ B2B)
Taiwan’s Industrial Technology Research Institute (ITRI), announced that in partnership with Metagone Biotech it has created Taiwan’s first ophthalmic technology platform targeting glaucoma and wet macular degeneration, developing the world’s first “dual-target” glaucoma drops and “no intraocular injection” wet macular degeneration drops to capture the USD 1.5 billion global ophthalmic market.
Taiwanese biotech, CancerFree Biotech, has been awarded the grand prize of USD 1 million in the final of “Meet the Drapers Season 5” entrepreneurship reality show for its innovative technology to develop an optimal treatment for cancer patients, beating 1,000 other teams from nine countries. Draper is an American venture capitalist whose investments include Paypal, Skype, and Tesla.
Ever Supreme Bio Technology reports progress on its cell therapy projects (CNyes, in Chinese)
Ever Supreme Bio Technology reported on its continued clinical research in the area of cell therapy, including cell therapy for acute myocardial infarction, which will enter Phase II clinical trials this year, while the company will submit an application for a Phase I/II clinical trial by the end of this year for its CAR-T cell therapy program for the treatment of solid cancers. According to the company, it is currently negotiating tech transfer and authorization rights with a number of international companies.